To verify this hypothesis, we applied genome-scale CRISPR-Cas9 knockout (GeCKO) screening to simultaneously knockout 19050 human genes in SNU-1 cells to explore whether BRCA2 monoallelic mutant tumor cells are selectively targeted by MMC55. Here, BRCA2 is linked to neoplasm.